EC Number   |
Application |
Reference  |
|---|
   3.4.17.23 | pharmacology |
ACE2 might be a target for treatment of non-small cell lung cancer |
710171 |
| 3.4.17.23 | medicine |
soluble ACE2 activity is a biomarker in heart failure, and in hypertension |
732780 |
| 3.4.17.23 | medicine |
antibodies and small molecular inhibitors that can block the interaction of the enzyme (ACE2) with the receptor binding domain can to combat the virus SARS-CoV-2 |
752692 |
| 3.4.17.23 | medicine |
regulation of NF-kappaB and ACE2 by specific Ang II type 1 receptor AT1 and Ang II type 2 receptor AT2 antagonists in a nongenetic model of type 2 diabetic nephropathy. The AT1 receptor and AT2 receptor antagonists lead to the repression and activation of the NF-kappaB signalling pathway, respectively. The blockade of AT2 receptor leads to an increase in ACE2 expression |
752845 |
| 3.4.17.23 | medicine |
angiotensin-converting enzyme 2 (ACE2) fused to the Fc portion of immunoglobulin neutralizes SARS-CoV-2 in vitro. Provision of soluble recombinant human ACE2 protein can be beneficial as a novel biologic therapeutic to combat or limit infection progression caused by coronaviruses that utilize ACE2 as a receptor. If given in its soluble form as an appropriate recombinant ACE2 protein, a new tool may be at hand to combat the spread of coronavirus in susceptible individuals by limiting coronavirus attachment to the cell membranes, cell entry, and replication |
753315 |
| 3.4.17.23 | medicine |
plasma kininase II or ACE levels are significantly increased by 18% in untreated diabetics when compared with healthy volunteers. After treatment for 6 weeks with metformin hydrochloride 500 mg twice daily there is a significant decrease of 20% in their ACE levels. Plasma prekallikrein levels are raised significantly by 28% in diabetic patients in contrast with the control subjects and the levels are reduced by 44% after treatment with metformin hydrochloride. NO levels are significantly decreased in plasma by 56% and in urine by 62% in untreated diabetic patients as compared with the healthy subjects. In treated diabetic patients' samples, there is an increase of 50% in plasma and 37% in urine samples compared to untreated patients |
753896 |
| 3.4.17.23 | medicine |
potential therapeutic approach to ACE2-mediated COVID-19. Treatment with a soluble form of ACE2 may exert dual functions, slow viral entry into cells and hence viral spread and protect the lung from injury |
753944 |
| 3.4.17.23 | analysis |
method for measurement of ACE2 activity in biological fluids, using hydrolysis of an intramolecularly quenched fluorogenic ACE2 substrate, in the absence or presence of the ACE2 inhibitors MLN-4760 or DX600. ACE2 detection ranges from 1.56 to 50 ng/ml. MLN-4760 potently inhibits the activity of both human and mouse ACE2, DX600 (linear form) only effectively blocks human ACE2 activity in this assay. In biological samples of human and mouse urine, cell culture medium from mouse proximal tubular cells, and mouse plasma, the mean intra- and interassay coefficients of variation of the assay range from 1.43 to 4.39 %, and from 7.01 to 13.17 %, respectively |
754628 |
| 3.4.17.23 | analysis |
method for measurement of ACE2 activity in biological fluids, using hydrolysis of an intramolecularly quenched fluorogenic ACE2 substrate, in the absence or presence of the ACE2 inhibitors MLN-4760 or DX600. ACE2 detection ranges from 1.56 to 50 ng/ml. MLN-4760 potently inhibits the activity of both human and mouse ACE2, DX600 (linear form) only effectively blocks human ACE2 activity in this assay. In biological samples of human and mouse urine, cell culture medium from mouse proximal tubular cells, and mouse plasma, the mean intra- and interassay coefficients of variation of the assay range from 1.43 to 4.39%, and from 7.01 to 13.17%, respectively |
754628 |
| 3.4.17.23 | analysis |
easy-to-use method for determining ACE2 activity in brain tissue and cerebrospinal fluid, based on a quenched fluorescent substrate and presence and absence of inhibitor DX600. The method can be adapted for other tissues, plasma, cell extracts, and cell culture supernatants |
754629 |
